Luigi Formisano

List of Publications by Year
in descending order

88 papers	3,221 citations	147786 31 h-index	168376 53 g-index
94 all docs	94 docs citations	94 times ranked	6252 citing authors

#	Article	IF	Citations
1	Identification and characterization of the promoter and transcription factors regulating the expression of cerebral sodium/calcium exchanger 2 (NCX2) gene. Cell Calcium, 2022, 102, 102542.	2.4	2
2	Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review. Critical Reviews in Oncology/Hematology, 2022, 172, 103649.	4.4	9
3	Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. JMIR Cancer, 2022, 8, e35930.	2.4	7
4	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. Critical Reviews in Oncology/Hematology, 2021, 157, 103191.	4.4	9
5	Quis Custodiet Ipsos Custodes (Who Controls the Controllers)? Two Decades of Studies on HDAC9. Life, 2021, 11, 90.	2.4	9
6	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. Expert Opinion on Drug Safety, 2021, 20, 1-10.	2.4	8
7	Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. Clinical Cancer Research, 2021, 27, 4379-4396.	7.0	30
8	Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. Cancers, 2021, 13, 4939.	3.7	3
9	Prolonged NCX activation prevents SOD1 accumulation, reduces neuroinflammation, ameliorates motor behavior and prolongs survival in a ALS mouse model. Neurobiology of Disease, 2021, 159, 105480.	4.4	8
10	FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188595.	7.4	13
11	Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma. International Journal of Molecular Sciences, 2021, 22, 1166.	4.1	10
12	GATA3 (GATA-Binding Protein 3)/KMT2A (Lysine-Methyltransferase-2A) Complex by Increasing H3K4-3me (Trimethylated Lysine-4 of Histone-3) Upregulates NCX3 (Na ⁺ -Ca ²⁺ Exchanger) Tj ETQq0 0 0 rgBT /Overlock 3680-3691.	2.0	4
13	The Transcriptional Complex Sp1/KMT2A by Up-Regulating Restrictive Element 1 Silencing Transcription Factor Accelerates Methylmercury-Induced Cell Death in Motor Neuron-Like NSC34 Cells Overexpressing SOD1-G93A. Frontiers in Neuroscience, 2021, 15, 771580.	2.8	1
14	HDAC4 and HDAC5 form a complex with DREAM that epigenetically down-regulates NCX3 gene and its pharmacological inhibition reduces neuronal stroke damage. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 2081-2097.	4.3	12
15	FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094797.	3.2	7
16	Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. ESMO Open, 2020, 5, e000885.	4.5	9
17	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nature Communications, 2020, 11, 5488.	12.8	25
18	c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?. Cancers, 2020, 12, 1489.	3.7	43

#	Article	IF	Citations
19	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. Journal of Clinical Medicine, 2020, 9, 675.	2.4	57
20	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. Cancer Cell, 2020, 37, 183-199.e5.	16.8	33
21	Transcriptional and epigenetic regulation of ncx1 and ncx3 in the brain. Cell Calcium, 2020, 87, 102194.	2.4	14
22	Mechanisms of resistance to mTOR inhibitors. Critical Reviews in Oncology/Hematology, 2020, 147, 102886.	4.4	27
23	Abstract GS6-06: A neoadjuvant trial with letrozole identifiesPRR11in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer. , 2020, , .		2
24	Abstract P3-06-08: Pak1 as a novel mediator of resistance to endocrine therapy and CDK4/6 inhibitors in ER+/PAK-1amplifiedbreast cancer. , 2020, , .		0
25	Abstract PD7-04: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance. , 2020, , .		0
26	Abstract P5-04-17: Hedgehog pathway is involved in cancer immune surveillance through PDL1 modulation. , 2020, , .		0
27	FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptorâ€“Positive (HR+) Breast Cancer. Clinical Cancer Research, 2019, 25, 6443-6451.	7.0	54
28	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers, 2019, 11, 981.	3.7	29
29	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1259.	3.7	18
30	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers, 2019, 11, 1419.	3.7	54
31	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer, 2019, 5, 31.	5.2	31
32	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications, 2019, 10, 1373.	12.8	252
33	Anti-miR-223-5p Ameliorates Ischemic Damage and Improves Neurological Function by Preventing NCKX2 Downregulation after Ischemia in Rats. Molecular Therapy - Nucleic Acids, 2019, 18, 1063-1071.	5.1	23
34	Dâ€Aspartate treatment attenuates myelin damage and stimulates myelin repair. EMBO Molecular Medicine, 2019, 11, .	6.9	44
35	Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Clinical Cancer Research, 2019, 25, 277-289.	7.0	74
36	Resveratrol treatment reduces the vulnerability of SH-SY5Y cells and cortical neurons overexpressing SOD1-G93A to Thimerosal toxicity through SIRT1/DREAM/PDYN pathway. NeuroToxicology, 2019, 71, 6-15.	3.0	25

#	Article	IF	Citations
37	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clinical Cancer Research, 2019, 25, 771-783.	7.0	29
38	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1235-1240.	1.7	9
39	Abstract 4402: FGFR1 signaling modulates estrogen-independent ER transcriptional activity in ER+/FGFR1-amplified breast cancer cells. , 2019, , .		0
40	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research, 2018, 24, 2517-2529.	7.0	26
41	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. OncoImmunology, 2018, 7, e1438106.	4.6	54
42	The miR206-JunD Circuit Mediates the Neurotoxic Effect of Methylmercury in Cortical Neurons. Toxicological Sciences, 2018, 163, 569-578.	3.1	20
43	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Frontiers in Oncology, 2018, 8, 608.	2.8	160
44	Abstract 1828: Hyperactivation of mTORC1 drives acquired resistance to the pan HER tyrosine kinase inhibitor neratinib in HER2 mutant cancers. , 2018, , .		0
45	Abstract 4008: ActivatingHER2 (ERBB2)mutations lead to endocrine therapy resistance through S6K activation. , 2018, , .		0
46	A Phase Ib Study of Alpelisib (BYL719), a PI3KÎ±-Specific Inhibitor, with Letrozole in ER+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34.	7.0	268
47	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research, 2017, 77, 2488-2499.	0.9	178
48	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. British Journal of Cancer, 2017, 116, 1425-1435.	6.4	76
49	An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. Journal of the National Cancer Institute, 2017, 109, .	6.3	29
50	Association of FGFR1 with ERÎ± Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clinical Cancer Research, 2017, 23, 6138-6150.	7.0	94
51	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine, 2017, 9, .	12.4	91
52	The neurotoxicant PCB-95 by increasing the neuronal transcriptional repressor REST down-regulates caspase-8 and increases Ripk1, Ripk3 and MLKL expression determining necroptotic neuronal death. Biochemical Pharmacology, 2017, 142, 229-241.	4.4	31
53	p38/Sp1/Sp4/HDAC4/BDNF Axis Is a Novel Molecular Pathway of the Neurotoxic Effect of the Methylmercury. Frontiers in Neuroscience, 2017, 11, 8.	2.8	34
54	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Scientific Reports, 2017, 7, 9388.	3.3	56

#	Article	IF	Citations
55	MC1568 Inhibits Thimerosal-Induced Apoptotic Cell Death by Preventing HDAC4 Up-Regulation in Neuronal Cells and in Rat Prefrontal Cortex. Toxicological Sciences, 2016, 154, 227-240.	3.1	24
56	Methylmercury upregulates RE-1 silencing transcription factor (REST) in SH-SY5Y cells and mouse cerebellum. NeuroToxicology, 2016, 52, 89-97.	3.0	32
57	Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Research, 2016, 76, 440-452.	0.9	93
58	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. Oncotarget, 2016, 7, 40073-40084.	1.8	15
59	Abstract 4508: Genomic profiling of ER+ breast cancers treated with prolonged neoadjuvant letrozole reveal a high frequency of NOTCH2 mutations in clinically resistant tumors. , 2016, , .		0
60	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research, 2015, 21, 4153-4164.	7.0	21
61	Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*. Molecular and Cellular Proteomics, 2015, 14, 1959-1976.	3.8	44
62	Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism. Journal of Neuroscience, 2015, 35, 7332-7348.	3.6	78
63	Extracellular signalâ€related kinase 2/specificity protein 1/specificity protein 3/repressor elementâ€1 silencing transcription factor pathway is involved in <scp>A</scp>roclor 1254â€induced toxicity in <scp>SHâ€SY5Y</scp> neuronal cells. Journal of Neuroscience Research, 2015, 93, 167-177.	2.9	17
64	MS-275 Inhibits Aroclor 1254â€“Induced SH-SY5Y Neuronal Cell Toxicity by Preventing the Formation of the HDAC3/REST Complex on the Synapsin-1 Promoter. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 236-243.	2.5	25
65	Resveratrol via sirtuin-1 downregulates RE1-silencing transcription factor (REST) expression preventing PCB-95-induced neuronal cell death. Toxicology and Applied Pharmacology, 2015, 288, 387-398.	2.8	38
66	Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treatment Reviews, 2015, 41, 877-883.	7.7	125
67	Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. Oncotarget, 2015, 6, 10563-10576.	1.8	24
68	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. Oncotarget, 2015, 6, 26090-26103.	1.8	37
69	MicroRNA-103-1 Selectively Downregulates Brain NCX1 and Its Inhibition by Anti-miRNA Ameliorates Stroke Damage and Neurological Deficits. Molecular Therapy, 2014, 22, 1829-1838.	8.2	63
70	Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. British Journal of Cancer, 2014, 111, 1168-1179.	6.4	49
71	Histone deacetylase 4 promotes ubiquitin-dependent proteasomal degradation of Sp3 in SH-SY5Y cells treated with di(2-ethylhexyl)phthalate (DEHP), determining neuronal death. Toxicology and Applied Pharmacology, 2014, 280, 190-198.	2.8	32
72	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. Breast Cancer Research, 2014, 16, R45.	5.0	56

#	Article	IF	Citations
73	The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. British Journal of Cancer, 2014, 110, 2887-2895.	6.4	80
74	Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models. Clinical Cancer Research, 2013, 19, 138-147.	7.0	87
75	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics, 2013, 13, 866-877.	2.2	21
76	Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. British Journal of Cancer, 2013, 108, 1616-1623.	6.4	15
77	Tumor-to-tumor metastasis. Anti-Cancer Drugs, 2013, 24, 759-764.	1.4	5
78	Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. British Journal of Cancer, 2013, 109, 686-693.	6.4	20
79	Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. OncoImmunology, 2013, 2, e25123.	4.6	3
80	Abstract 950: Src tyrosine kinase contributes to lapatinib resistance in human breast cancer models.. , 2013, , .		0
81	Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models.. Journal of Clinical Oncology, 2012, 30, e13509-e13509.	1.6	1
82	Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. World Journal of Clinical Oncology, 2012, 3, 111.	2.3	14
83	Decision making in clinical stage I (CSI) testicular cancer (TC).. Journal of Clinical Oncology, 2012, 30, e15034-e15034.	1.6	0
84	The Repressor Element 1-Silencing Transcription Factor Is a Novel Molecular Target for the Neurotoxic Effect of the Polychlorinated Biphenyl Mixture Aroclor 1254 in Neuroblastoma SH-SY5Y Cells. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 997-1003.	2.5	22
85	Paraneoplastic Sensitive Neuropathy Associated with Anti-Hu Antibodies in a Neuroendocrine Tumor of Duodenum: A Case Report. International Journal of Immunopathology and Pharmacology, 2010, 23, 1281-1285.	2.1	4
86	The Two Isoforms of the Na⁺/Ca²⁺Exchanger, NCX1 and NCX3, Constitute Novel Additional Targets for the Prosurvival Action of Akt/Protein Kinase B Pathway. Molecular Pharmacology, 2008, 73, 727-737.	2.3	55
87	Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant Cancers. SSRN Electronic Journal, 0, , .	0.4	0
88	FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. Future Oncology, 0, , .	2.4	0